formulary

Readers read, we listen: Our top 10 of 2016, chosen by you

Readers are full of surprises. Sometimes, stories we editors put on top of the news don’t make the cut with readers. Others are unexpected hits. Still others resurface from the past. Find all three in this year's roundup of 2016 news curated by you, our readers.

Medicare adds to the squeeze on Novo, Sanofi insulins

Just over a year ago, Sanofi and Novo Nordisk were touting their new basal insulins as fuel for their diabetes growth engines. But several payers have clamped down on those new meds--Toujeo and Tresiba, respectively--and now, Medicare Part D plans are adding to the pressure.